Written Question·Department of Health and Social Care·UIN 45873

Glioblastoma: Immunotherapy

Tabled: 17 April 2025

Answered: 28 April 2025

Question

Sarah Owen

To ask the Secretary of State for Health and Social Care, whether his Department plans to work with the National Institute for Health and Care Excellence to expedite market access to the personalised immunotherapy developed to treat the malignant brain tu

Answer

Karin Smyth

DCVax-L has not yet been licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the United Kingdom. The manufacturer has confirmed that it has submitted an application, and it is fully engaged with the Marketing Authorisatio...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 45873) →

Partner sites